Label: OTIPRIO- ciprofloxacin suspension
- NDC Code(s): 69251-201-01
- Packager: Otonomy, Inc.
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: New Drug Application
Updated September 29, 2021
If you are a consumer or patient please visit this version.
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use OTIPRIO safely and effectively. See full prescribing information for OTIPRIO.
OTIPRIO® (ciprofloxacin otic suspension), for intratympanic or otic use
Initial U.S. Approval: 1987
INDICATIONS AND USAGE
OTIPRIO is a fluoroquinolone antibacterial indicated for the following conditions:
DOSAGE AND ADMINISTRATION
- OTIPRIO is for intratympanic or otic administration by a healthcare professional only. (2.1)
- OTIPRIO is intended for single-patient use with up to two doses available in each vial. (2.1)
- For bilateral otitis media with effusion, administer OTIPRIO as a single intratympanic administration of one 0.1 mL (6 mg) dose into each affected ear, following suctioning of the middle ear effusion. (2.1)
- For acute otitis externa, administer OTIPRIO as a single 0.2 mL (12 mg) administration to the affected ear(s). (2.1)
- See Full Prescribing Information for directions for OTIPRIO dose preparation. (2.2)
DOSAGE FORMS AND STRENGTHS
Otic Suspension: Each OTIPRIO vial contains 1 mL of 6% (60 mg/mL) ciprofloxacin otic suspension. (3)
OTIPRIO is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to quinolones, or to any component of OTIPRIO. (4)
WARNINGS AND PRECAUTIONS
Potential for Microbial Overgrowth: OTIPRIO may result in overgrowth of non-susceptible bacteria and fungi. (5.1)
Otitis Media with Effusion: The most frequently occurring adverse reactions (with an incidence rate greater than 3%) were nasopharyngitis and irritability. (6.1)
Acute Otitis Externa: There were no adverse reactions that occurred in at least 3% of OTIPRIO patients and at an incidence greater than sham. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Otonomy at 1-800-826-6411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.
Table of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
- Sections or subsections omitted from the full prescribing information are not listed.
- 1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
2.1 Dosage and Important Administration Instructions
- OTIPRIO is for intratympanic or otic administration by a healthcare professional only.
- OTIPRIO is intended for single-patient use, discard unused portion.
- For bilateral otitis media with effusion, administer OTIPRIO as a single intratympanic administration of one 0.1 mL (6 mg) dose into each affected ear of pediatric patients (6 months of age and older), following suctioning of middle ear effusion.
- For acute otitis externa, administer OTIPRIO as a single 0.2 mL (12 mg) administration to the external ear canal of each affected ear of patients aged 6 months and older.
2.2 Preparation of OTIPRIO
Directions for OTIPRIO dose preparation and handling are presented in Figure 1.The directions differ for each indication. Follow the correct directions.
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5 WARNINGS AND PRECAUTIONS
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Otitis Media with Effusion
In two randomized, sham-controlled Phase 3 clinical trials, 530 pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement were treated with OTIPRIO or sham administered intratympanically as a single dose. The median age of the pediatric patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age.
Adverse reactions that occurred in at least 3% of OTIPRIO patients and at an incidence greater than sham are presented in Table 1.
Table 1: Adverse Reactions in Phase 3 Otitis Media with Effusion Trials Adverse Reactions OTIPRIO
Nasopharyngitis 5% 4% Irritability 5% 3% Rhinorrhea 3% 2%
Acute Otitis Externa
In a single randomized, sham controlled Phase 3 clinical trial, 259 pediatric and adult patients with acute otitis externa were treated with OTIPRIO or sham administered by a healthcare professional to the external ear canal as a single dose (0.2 mL to each affected ear). The median age of the patients enrolled in the clinical trial was 34 years; 26% were pediatric patients (age 3 to 17 years), 65% were adults (age 18 to 64 years), and 8% were elderly patients (age 65 years and older).
Adverse reactions that occurred in at least 2% of OTIPRIO patients and at an incidence greater than sham are presented in Table 2.
Table 2: Adverse Reactions in Phase 3 Acute Otitis Externa Trial Adverse Reactions OTIPRIO
Ear Pruritus 2% 2% Headache 2% 1% Otitis Media 2% 1% Ear Discomfort 2% 0%
8 USE IN SPECIFIC POPULATIONS
Animal reproduction studies have not been conducted with OTIPRIO. No adequate and well-controlled studies have been performed in pregnant women. Because of the negligible systemic exposure associated with clinical administration of OTIPRIO, this product is expected to be of minimal risk for maternal and fetal toxicity when administered to pregnant women.
Ciprofloxacin is excreted in human milk with systemic administration. However, because of the negligible systemic exposure after otic application, nursing infants of mothers receiving OTIPRIO should not be affected.
8.4 Pediatric Use
The safety and effectiveness of OTIPRIO in infants below six months of age have not been established.
The safety and effectiveness of OTIPRIO was established in 530 pediatric patients with bilateral otitis media with middle ear effusion undergoing myringotomy with tympanostomy tube placement. The median age of patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age [see Adverse Reactions (6.1) and Clinical Studies (14)].
The safety and effectiveness of OTIPRIO was established in 64 acute otitis externa pediatric patients that participated in the pivotal Phase 3 study. Efficacy observed in the pediatric patients in that study was no different from the older population. [see Adverse Reactions (6.1) and Clinical Studies (14)]
8.5 Geriatric Use
Clinical studies of OTIPRIO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients [see Adverse Reactions (6.1) and Clinical Studies (14)].
OTIPRIO (ciprofloxacin otic suspension) 6% contains the synthetic fluoroquinolone antibacterial, ciprofloxacin. OTIPRIO is for intratympanic administration for otitis media with effusion and otic administration to the external ear canal for acute otitis externa. OTIPRIO is supplied as a white, preservative-free, sterile otic suspension of 6% (w/v) ciprofloxacin in a neutral pH, buffered, isotonic solution in a single-patient use glass vial with a latex-free rubber stopper containing 1 mL. The inactive ingredients are poloxamer 407, sodium chloride, tromethamine, hydrochloric acid and water for injection (WFI).
The thermosensitive suspension exists as a liquid at room temperature or below and gels when warmed [see How Supplied/Storage and Handling (16)].
Ciprofloxacin has the following nomenclature:
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid. Its empirical formula is C17H18FN3O3 and its molecular weight is 331.3.
Its chemical structure is as follows:
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Ciprofloxacin is a fluoroquinolone antibacterial [see Microbiology (12.4)].
The plasma concentration of ciprofloxacin following otic administration of OTIPRIO was not measured.
Mechanism of Action
The bactericidal action of ciprofloxacin results from interference with the enzyme DNA gyrase, which is needed for the synthesis of bacterial DNA.
Bacterial resistance to fluoroquinolones can develop through chromosomally- or plasmid-mediated mechanisms. In vitro studies demonstrated cross-resistance between ciprofloxacin and some fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of antibacterial agents, such as beta-lactams or aminoglycosides.
Ciprofloxacin has been shown to be active against most isolates of the following bacteria:
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Eight in vitro mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below:
Salmonella/Microsome Test (Negative)
Escherichia coli DNA Repair Assay (Negative)
Mouse Lymphoma Cell Forward Mutation Assay (Positive)
Chinese Hamster V79 Cell HGPRT Test (Negative)
Syrian Hamster Embryo Cell Transformation Assay (Negative)
Saccharomyces cerevisiae Point Mutation Assay (Negative)
Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative)
Rat Hepatocyte DNA Repair Assay (Positive)
Thus, 2 of the 8 in vitro tests were positive, but results of the following 3 in vivo test systems gave negative results:
Rat Hepatocyte DNA Repair Assay
Micronucleus Test (Mice)
Dominant Lethal Test (Mice)
Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg in mice and 250 mg/kg in rats (for mice and rats respectively, approximately 300 and 200 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated with OTIPRIO) were administered for up to 2 years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species.
Fertility studies performed in rats at oral doses of ciprofloxacin up to 100 mg/kg/day revealed no evidence of impairment. This would be approximately 80 times the maximum recommended clinical dose of ototopical ciprofloxacin based upon body surface area, assuming total absorption of ciprofloxacin from the ear of a patient treated with OTIPRIO.
14 CLINICAL STUDIES
14.1 Bilateral Otitis Media with Effusion
Two randomized, multicenter, sham-controlled clinical trials in 532 pediatric patients with bilateral otitis media with effusion undergoing myringotomy with tympanostomy tube placement evaluated the safety and efficacy of OTIPRIO when administered intratympanically as a single dose (NCT 01949155 and NCT 01949142). The median age of patients enrolled in the clinical trials was 1.5 years; 62% of patients were 6 months through 2 years of age and 38% of patients were greater than 2 years of age. The efficacy endpoint for both trials was the cumulative proportion of study treatment failures through Day 15, defined as the occurrence of any of the following events: otorrhea as determined by a blinded assessor on or after 3 days post-surgery, otic or systemic antibacterial drug use for any reason any time post-surgery, as well as patients who missed visits or were lost-to-follow-up. Table 3 presents the results from each Phase 3 trial.
Table 3: Cumulative Proportion of Treatment Failures Through Day 15 in Phase 3 Trials (Otitis Media with Effusion) 1 the earliest occurring treatment failure event, and patients were classified as a treatment failure due only to that component for the remainder of the study
2 P-value <0.001 for Cochran-Mantel-Haenszel test (adjusted for age-group)
Trial 1 (N=266) Trial 2 (N=266) OTIPRIO Sham Difference
(Sham – OTIPRIO)
OTIPRIO Sham Difference
(Sham – OTIPRIO)
Treatment Failure 25%
Reason for Failure1 Otorrhea 7% 11% 7% 27% Otic antibacterial drugs 6% 17% 5% 8% Systemic
2% 5% 3% 3% Lost-to-follow-up and missed visit 10% 11% 6% 7%
Administration of OTIPRIO did not lead to impairment in hearing function, middle ear function or tube patency by Day 29.
14.2 Acute Otitis Externa
One randomized multicenter, sham-controlled clinical trial in 262 pediatric and adult patients with unilateral or bilateral acute otitis externa was designed to evaluate the safety and efficacy of OTIPRIO when administered by a healthcare professional as a single dose to the external ear canal to patients aged 6 months and older (NCT 02801370). The median age of patients enrolled in the clinical trials was 34 years; 26% of patients were 3 to 17 years of age, 65% of patients were 18 to 64 years of age, and 8% of patients were greater than 65 years of age. No patients less than 3 years of age were enrolled.
The primary efficacy endpoint was the proportion of patients with clinical response at Day 8. Clinical response was defined as the complete absence of signs and symptoms of acute otitis externa (i.e., tenderness, erythema, edema, and otorrhea as determined by the blinded assessor), and no concomitant systemic or topical antibacterial drug (given in the study ear) was taken for any reason at or prior to the study visit. Table 4 contains the proportions of patients with clinical response at Day 8 in both the intent to treat (ITT) population which contains all subjects who were randomized and did not have group A streptococci cultured on Day 1 and the microbiological ITT population which contains all ITT subjects who had a positive culture for S. aureus or P. aeruginosa on Day 1.
Table 4: Proportion of Patients with Clinical Response at Study Day 8 (Acute Otitis Externa) 1 p<0.001 from a Fisher’s exact test
2 p=0.012 from a Fisher’s exact test
ITT population = all patients who were randomized and did not have group A streptococci cultured on Day 1.
Mic-ITT population = all ITT patients who had a positive culture for S. aureus or P. aeruginosa on Day 1.
Study Population OTIPRIO Sham % Difference
(OTIPRIO - Sham)
Intention to Treat (ITT)
Microbiological ITT (Mic-ITT)
16 HOW SUPPLIED/STORAGE AND HANDLING
OTIPRIO is a sterile, preservative-free, otic suspension of 6% (60 mg/mL, w/v) ciprofloxacin in a neutral pH buffered, isotonic solution containing poloxamer 407.
Each OTIPRIO carton contains 1 mL of 6% (60 mg/mL, w/v) ciprofloxacin in a 2 mL single-patient use glass vial fitted with a latex-free rubber stopper. (NDC 69251-201-01)
OTIPRIO should be stored at 2 to 8°C (36 to 46°F) until prior to use to prevent thickening during preparation. Protect from light. Store in the original carton until dose preparation.
17 PATIENT COUNSELING INFORMATION
Advise patients and their caregiver(s) that there may be drainage from the ear the first few days following ear tube surgery, but if the ear becomes painful, or continuous ear discharge is noted, or the patient develops a fever, advise patients and their caregiver(s) to consult their physician.
For acute otitis externa, advise patients and/or their caregivers that if the ear continues to be painful, swollen or itchy after a week, they should consult their physician.
San Diego, CA 92121
OTIPRIO® is a registered trademark of Otonomy.
U.S. Patent Nos: 8,318,817, 9,205,048, 9,220,796, 9,233,068, 9,486,405, and 9,603,796
- PRINCIPAL DISPLAY PANEL - NDC: 69251-201-01 - 1mL Vial Label
- PRINCIPAL DISPLAY PANEL - NDC: 69251-201-01 - 1ml Carton Label
INGREDIENTS AND APPEARANCE
Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69251-201 Route of Administration INTRATYMPANIC, AURICULAR (OTIC) Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength CIPROFLOXACIN (UNII: 5E8K9I0O4U) (CIPROFLOXACIN - UNII:5E8K9I0O4U) CIPROFLOXACIN 60 mg in 1 mL Inactive Ingredients Ingredient Name Strength POLOXAMER 407 (UNII: TUF2IVW3M2) SODIUM CHLORIDE (UNII: 451W47IQ8X) TROMETHAMINE (UNII: 023C2WHX2V) HYDROCHLORIC ACID (UNII: QTT17582CB) WATER (UNII: 059QF0KO0R) Product Characteristics Color WHITE (preservative-free, sterile otic suspension) Score Shape Size Flavor Imprint Code Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69251-201-01 1 in 1 CARTON 02/11/2016 06/30/2022 1 1 mL in 1 VIAL, SINGLE-USE; Type 0: Not a Combination Product Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA207986 02/11/2016 06/30/2022 Labeler - Otonomy, Inc. (025801111)